by Georgia State University Transmission electron micrograph of RSV. Credit: CDC/ Dr. Erskine Palmer / Public Domain An oral antiviral drug that targets a key part of the respiratory syncytial virus (RSV) polymerase and inhibits the synthesis of viral genetic material has been identified, a finding that could provide an effective treatment against RSV disease,...
by Perelman School of Medicine at the University of Pennsylvania Colorized scanning electron micrograph of an apoptotic cell (green) heavily infected with SARS-COV-2 virus particles (yellow), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: NIH/NIAID Researchers have identified a powerful combination of antivirals to...
The move gives doctors and high-risk patients an additional option for treating mild-to-moderate illness caused by the coronavirus By Laurie McGinley, January 21, 2022 at 7:20 p.m. EST Federal regulators Friday approved the use of the antiviral drug remdesivir for covid-19 outpatients at high risk of being hospitalized, providing a new treatment option for doctors...
by Georgia State University Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: NIAID The COVID-19 pandemic and resurgence of infections by other respiratory RNA viruses such as respiratory syncytial virus (RSV) in children has caused an...
by NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: NIAID The experimental drug TEMPOL may be a promising oral antiviral treatment for COVID-19, suggests a study of cell...
A new antiviral drug that induces mutations in the genetic material of influenza virus is highly effective in treating infection in animals and human airway tissue, a new study shows. The antiviral drug blocks RNA polymerase, the enzyme that plays a central role in replicating the genome of influenza virus, causing mutations in the viral...
In a significant advance in improving the safety of donor stem cell transplants, a major clinical trial led by researchers at Dana-Farber Cancer Institute and Brigham and Women’s Hospital (BWH) has shown that a novel agent can protect against the most common viral infection that patients face after transplantation. The results represent a breakthrough in...
